Durbin Letter To USPlabs Targets Latest Supplement Adulterant
This article was originally published in The Tan Sheet
USPlabs is under the spotlight again as perennial supplement industry critic Sen. Dick Durbin inquires about the firm’s adverse event records and other regulatory credentials. The latest supplement controversy could bolster Durbin’s efforts to tighten supplement regulations.
You may also be interested in...
DEA says more kratom was seized from US firms in the first half of 2016 than in any previous year, but the seizures came two years after FDA imposed an import alert to stop shipments and three years after the agency stumbled out of the gate in determining whether the ingredient could be used in supplements.
FDA adds acetaminophen warnings; CHPA suggests 4-aminophenol standard; OTC HSA bill in House; supplement registration bill reintroduced; FSMA user fees still on hold; more scrutiny of energy drinks; and Public Citizen pans OTC Oxytrol.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.